Anticholinergic exposure and constipation in children

Do not let a score replace the symptom history

When a child has constipation, a medication review can be useful, but the symptom needs its own clinical assessment. A burden category does not establish the cause, severity, or appropriate treatment. The review should start with the child’s bowel history and the actual medicines used during the relevant period.

This guide explains how to connect those records. It does not provide a laxative regimen, a medication-stopping rule, or a diagnostic checklist intended to replace pediatric care.

Describe the bowel concern concretely

Record the pattern, duration, discomfort, and change from the child’s usual experience, using the child’s report and caregiver observations as appropriate. A broad label of “constipation” can conceal different clinical histories. The assessor needs to know what prompted concern and how it evolved.

NIDDK notes that constipation in children has several possible causes, including behavioral patterns, health conditions, and some medicines. NIDDK: constipation in children A medication association should therefore be considered alongside other explanations rather than treated as established because a classified medicine is present.

Reconstruct the medication timeline

Identify the exact products, preparations, instructions, and actual administration. Include occasional and nonprescription products as well as scheduled medicines. Note recent additions or changes and whether the bowel concern was present before them.

Timing can help identify a question worth assessing, but it does not prove causality. A medicine may have been added during a period when illness, intake, routine, or other treatment also changed. The clinical note should preserve those events rather than reduce the history to a single source total.

Use product-specific warnings when available

Some products have direct warnings relevant to bowel function. Glycopyrrolate oral-solution labeling, for example, identifies constipation as an important adverse reaction and warns about intestinal pseudo-obstruction. Those are product-specific safety statements, distinct from an adult ordinal burden category. DailyMed: glycopyrrolate oral solution

The example does not imply that the child is taking glycopyrrolate or experiencing that complication. It shows why a medicine-specific warning should be read directly when relevant. A missing scale row cannot negate such a warning, and a burden score cannot assess the clinical seriousness of a current symptom.

Read the source table without filling gaps

If UnifiedACB has an observation for a current medicine, retain the original source, version, value, and any formulation qualifier. If it does not, state the gap. A medicine’s absence from a source is not evidence that it cannot contribute to the clinical problem.

Do not construct a pediatric constipation-risk score by adding or averaging categories from different scales. The source classifications were not created by this article and do not provide a validated estimate of a child’s bowel outcome.

Distinguish symptom evidence from cognitive evidence

A pediatric study of cognition cannot establish whether a medicine contributes to constipation. Likewise, a report of bowel symptoms is not proof of cognitive harm. The outcome under discussion determines which source evidence is relevant.

This prevents a common overgeneralization: using reassuring cognitive findings to dismiss a peripheral symptom, or using a peripheral symptom to predict long-term cognitive effects. Each claim requires its own evidence and appropriate population context.

Document benefit as well as the concern

The medicine may be treating an important condition or symptom. Record that purpose and any observed benefit so the clinical team can assess options with the full history. A source classification alone does not determine that stopping treatment is appropriate or that another medicine is equivalent.

If the team makes a change, the bowel outcome and the original treatment goal should be followed separately. A lower classification does not prove that constipation has resolved, and symptom improvement does not by itself prove the mechanism that caused it.

A useful review output

The review should leave a clear bowel history, reconciled medication use, relevant product-specific warnings, original source observations, and unresolved clinical questions. It should identify who will assess the symptom and follow the plan. Current symptoms requiring medical assessment should not be held up by an incomplete evidence lookup.

Limits

The framework does not diagnose constipation or establish an individual causal link. Pediatric outcomes, underlying conditions, and formulations vary. The useful contribution is to make possible medication contributors visible while preserving a full clinical assessment and avoiding an adult score-driven treatment rule.

References

1. American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2023;71:2052-2081. Source
2. Vennard O, Stewart C, Tolia M, Soiza RL, Myint PK. Anticholinergic Medication Burden Scales: A Systematic Review. J Am Geriatr Soc. 2026;74(6):1771-1784. Source
3. Feinstein JA, et al. Anticholinergic Medications and Parent-Reported Anticholinergic Symptoms in Neurologically Impaired Children. J Pain Symptom Manage. 2023;65(2):e109-e114. Source
4. Hong IS, Bishop JR. Anticholinergic use in children and adolescents after initiation of antipsychotic therapy. Ann Pharmacother. 2010;44(7-8):1171-1180. Source
5. Ghezzi E, Chan M, Kalisch Ellett LM, et al. The effects of anticholinergic medications on cognition in children: a systematic review and meta-analysis. Sci Rep. 2021;11:219. Source
6. National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms & Causes of Constipation in Children. Source
7. DailyMed. Glycopyrrolate oral solution: prescribing information. National Library of Medicine. Sections on indications, warnings, adverse reactions, and pediatric use. Source

Disclosure

Funding: None. Conflict of interest: None declared for the UnifiedACB educational project.

Educational evidence summary. This content does not provide patient-specific medical advice and does not replace clinical judgment, medication reconciliation, or prescribing guidance.